Dacarbazine and Fotemustine for Melanoma
Author Information
Author(s): S.M. Lee, G.P. Margison, A.A. Woodcock, N. Thatcher
Primary Institution: Christie Hospital NHS Trust
Hypothesis
Can sequential administration of varying doses of dacarbazine and fotemustine improve response rates in advanced malignant melanoma?
Conclusion
The study suggests that increasing the dose of dacarbazine does not significantly improve response rates but does increase haematological toxicity.
Supporting Evidence
- Eighteen of the 60 patients responded to therapy, with an overall response rate of 30%.
- Median survival was 3.6 months, with no significant difference between different DTIC doses.
- Severe haematological toxicity increased with higher doses of DTIC.
Takeaway
Doctors tested two cancer drugs to see if giving them in a certain order helps patients with melanoma. They found that while more medicine didn't help much, it did make patients feel worse.
Methodology
Sixty patients with metastatic melanoma received varying doses of dacarbazine followed by fotemustine, with treatment cycles repeated every 28 days.
Limitations
The small sample size may limit the generalizability of the findings.
Participant Demographics
Median age was 55 years, with 28 males and 32 females.
Statistical Information
P-Value
0.67
Statistical Significance
p=0.67
Want to read the original?
Access the complete publication on the publisher's website